Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD4 | P21917 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23772904 | 1.00 | MEN1 (0.42) | MEN1KMT2ACES2POLBSMN1; SMN2 | |
| SCHEMBL23772913 | 1.00 | MEN1 (0.42) | MEN1KMT2ACES2POLBSMN1; SMN2 | |
| SCHEMBL23696139 | 1.00 | MEN1 (0.42) | MEN1KMT2ACES2POLBSMN1; SMN2 | |
| SCHEMBL5066367 | 0.89 | MEN1 (0.50) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL22821424 | 0.87 | MEN1 (0.47) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL23772768 | 0.86 | MEN1 (0.42) | MEN1KMT2ACES2POLBSMN1; SMN2 | |
| SCHEMBL23772817 | 0.86 | MEN1 (0.42) | MEN1KMT2ACES2POLBSMN1; SMN2 | |
| SCHEMBL23772815 | 0.86 | MEN1 (0.42) | MEN1KMT2ACES2POLBSMN1; SMN2 | |
| SCHEMBL23943291 | 0.83 | MAPK1 (0.41) | MEN1KMT2APOLBSMN1; SMN2KDM4E | |
| SCHEMBL25729763 | 0.83 | MEN1 (0.40) | MEN1KMT2APOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885CES2 1669/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MEN1 4055/4885KMT2A 445/4885CES2 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.